Aquestive Therapeutics Inc

Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a pharmaceutical company aiming to solve patients’ problems by advancing current standards of care through simplifying complex delivery methods. Aquestive is developing orally administered products to provide novel alternatives to invasive and inconvenient standard of care therapies. Aquestive is advancing a late-stage proprietary product pipeline focused on treating diseases of the central nervous system, or CNS, and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis.